IXJ provides valuable global diversification with 110 holdings across multiple countries (70% U.S., with exposure to Switzerland, U.K., and Japan), but underperforms XLV in returns and charges a higher expense ratio. It's a viable option for investors prioritizing international exposure despite higher costs.
Positioned as a stable, dividend-focused option with lower volatility and international diversification. While it underperforms XBI on recent returns, it offers consistent 1.4% dividend yield and lower risk profile suitable for conservative investors.
Recommended as the better choice due to broader diversification (110 holdings), lower maximum drawdown (18.1%), superior 5-year and 10-year returns (4.9% and 8.5% annualized), higher dividend yield (1.5%), and more stable global exposure across developed and emerging markets.
Lower expense ratio (0.40%), broader diversification across 110 companies, more stable with lower maximum drawdown (18.10%), and anchored by established leaders like Eli Lilly, Johnson & Johnson, and AbbVie. Recommended for defensive healthcare exposure.
Offers higher dividend yield (1.47%), lower volatility (beta 0.52), greater diversification with 110 holdings, and stronger 5-year total return ($1,251 on $1,000 invested). Better suited for conservative and income-seeking investors.
IXJ is presented as a solid alternative offering broader diversification with 110 global holdings, lower expense ratio (0.40%), and higher dividend yield (1.50%), but is not recommended due to underperformance relative to PJP in most performance metrics.
Recommended for diversification-focused investors due to broader exposure across 110 international holdings, multiple healthcare subsectors (pharmaceuticals, medical devices, services, insurance), and lower concentration risk. Better positioned to weather sector-specific challenges.
IXJ demonstrated superior performance with higher 5-year total returns ($1,257 vs. $1,177), lower volatility (beta 0.56), lower maximum drawdown (18.1% vs. 22%), double the dividend yield (1.50% vs. 0.70%), and significantly higher AUM ($4.1B vs. $734.1M), making it the more compelling choice for most healthcare investors.
Offers valuable international diversification and similar dividend yields to FHLC, but the higher expense ratio (5x more expensive) and lower historical returns make it less attractive despite broader geographic reach.
Provides diversified global healthcare exposure with lower concentration risk but also lower recent returns (10%); offers smoother risk profile for long-term investors.
Articles that tag IXJ but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology